EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice

Daisuke Yabe iD, Yoshiyuki Hamamoto iD, Daiji Kawanami iD, Rimei Nishimura, Yasuo Terauchi, Hanan Amadid, Uffe Christian Braae, Atheline Major-Pedersen, Ryo Suzuki iD

Journal of Diabetes Investigation · 2024-11 · 15 (11) · 1566-1577

DOI: 10.1111/jdi.14291 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 22.08.2024. Verfasst von Daisuke Yabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Glycated Hemoglobin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction PIONEER REAL Japan was a non‐interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Materials and Methods Adults naïve to injectable glucose‐lowering therapies initiated oral semaglutide in routine clinical practice and were followed for 34–44 weeks. The primary endpoint was change in glycated hemoglobin (HbA 1c ) from baseline to end of study; the co‐primary endpoint was number of adverse events (AEs). Secondary endpoints included change in bodyweight from baseline to end of study. Analyses were also carried out for subgroups aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinHumansMaleFemaleProspective StudiesAgedJapanMiddle AgedAdministration, OralBlood GlucoseBody WeightAdultTreatment OutcomeEast Asian PeopleSemaglutide

Stichwörter der Autor:innen

Diabetes mellitus, type 2Oral semaglutideProspective studies

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinBlood GlucoseSemaglutidehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan.
  • Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan.
  • Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
  • Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.

ORCID-Profile: Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, Ryo Suzuki

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Yabe, D., Hamamoto, Y., Kawanami, D., Nishimura, R., Terauchi, Y., Amadid, H., Braae, U. C., Major-Pedersen, A., & Suzuki, R. (2024). PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Journal of Diabetes Investigation, 15(11), 1566-1577. https://doi.org/10.1111/jdi.14291

Vancouver

Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, et al. PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Journal of Diabetes Investigation. 2024;15(11):1566-1577. doi:10.1111/jdi.14291

BibTeX
@article{Yabe2024,
  author = {Yabe, Daisuke and Hamamoto, Yoshiyuki and Kawanami, Daiji and Nishimura, Rimei and Terauchi, Yasuo and Amadid, Hanan and Braae, Uffe Christian and Major-Pedersen, Atheline and Suzuki, Ryo},
  title = {PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  volume = {15},
  number = {11},
  pages = {1566--1577},
  doi = {10.1111/jdi.14291}
}
Kostenlos starten →